Recognising that clodrolip-mediated depletion of TAMs might not be effective enough for complete suppression of tumour growth, we combined clodrolip with an antiangiogenic therapy by systemic application of anti-VEGF antibodies. The gene discussed is VEGFA; the disease is neoplasm.